Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892333 · ClinicalTrials.gov registry record
Large Abdominal Hernia Repair With SurgiMend 3.0
A clinical trial, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- 122
- Enrollment target
NCT00892333: Completed study, sponsored by Integra LifeSciences Corporation.
NCT00892333 is a clinical trial that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00892333 has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- 122 participants
- Enrollment target
Study Summary
The rate of hernia recurrence at one year following repair of a large abdominal hernia with a biologic mesh is high, ranging from 30% to 100%, with a reported historic average rate of 40%. The purpose of this study is to evaluate the rate of hernia recurrence at one year following repair with SurgiMend 3.0, an FDA-cleared novel biologic mesh, the hypothesis being that such rate will be less than 20% at one year, representing a 50% reduction over the historic rate of 40%.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-07 |
What the finished NCT00892333 record still lists
NCT00892333 is an observational study that tracks outcomes without assigning an intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00892333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00892333 about?
NCT00892333 is a clinical study titled "Large Abdominal Hernia Repair With SurgiMend 3.0". The rate of hernia recurrence at one year following repair of a large abdominal hernia with a biologic mesh is high, ranging from 30% to 100%, with a reported historic average rate of 40%. The purpose of this study is to evaluate the rate of hernia recurrence at one year following repair with SurgiM...
What is the current status of trial NCT00892333?
This trial is currently completed. The enrollment target is 122 participants. The study started on 2009-04. Estimated completion is 2014-07.
Who is sponsoring clinical trial NCT00892333?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia